The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRMDL.L Regulatory News (RMDL)

  • There is currently no data for RMDL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Hardman & Co Research: RM Secured Direct Lending (RMDL): Predictable revenue streams generating high yield

5 Jun 2019 09:22

Hardman & Co Research Hardman & Co Research: RM Secured Direct Lending (RMDL): Predictable revenue streams generating high yield 05-Jun-2019 / 09:21 GMT/BST


Hardman & Co Research: Predictable revenue streams generating high yield

THIS DOCUMENT IS NOT AVAILABLE TO 'U.S. PERSONS', NOR TO PARTIES WHO ARE NOT CONSIDERED 'RELEVANT PERSONS' IN THE UNITED KINGDOM, NOR SHOULD IT BE TAKEN, TRANSMITTED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, TO EITHER OF THESE CATEGORIES. SEE PAGE 3 FOR FURTHER DETAILS.

RM Secured Direct Lending (RMDL) offers investors an ongoing ca.6.5% dividend yield, whose sustainability is supported by multi-year assets, a rising revenue yield and economies of scale. Credit, we believe, is well controlled, and we provide readers with a detailed review of its assessment, monitoring and recovery. We believe the gearing level is appropriate, the investment manager's interests are aligned to shareholders, and that any discount will be actively managed. Like any lender, there are risks when the cycle turns; also, RMDL has some junior debt positions, and its book has shown a propensity to turn over, which in the future could see more external refinancing. The shares trade at a 3% premium to NAV. Please click here for the full report:

https://www.hardmanandco.com/research/corporate-research/predictable-revenue-streams-generating-high-yield/

To contact us: Hardman & Co 35 New Broad Street London EC2M 1NH www.hardmanandco.comFollow us on Twitter @HardmanandCo Contacts: Mark Thomas +44 20 7194 7622 mt@hardmanandco.com

Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

819689 05-Jun-2019 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
20th Jul 20215:29 pmRNSHolding(s) in Company
16th Jul 20212:31 pmRNSInvestment Manager's Holding
16th Jul 20217:00 amRNSNet Asset Value(s)
15th Jul 20219:30 amRNSHolding(s) in Company
9th Jul 20217:00 amRNSIrrevocable Share Repurchase Programme
16th Jun 20217:00 amRNSNet Asset Value(s)
8th Jun 20214:22 pmRNSResult of AGM
26th May 20217:00 amRNSDividend Declaration
17th May 20217:00 amRNSNet Asset Value(s)
12th May 20217:00 amRNSRefreshed investment focus & Company name change
19th Apr 20214:37 pmRNSInvestment Manager's Holding
16th Apr 20215:46 pmRNSHolding(s) in Company
16th Apr 20217:00 amRNSNet Asset Value(s)
6th Apr 202111:17 amRNSResult of General Meeting
29th Mar 20217:00 amRNSFinal Results
29th Mar 20217:00 amRNSUpdate on ZDP Shares and New Loan Facility
29th Mar 20217:00 amRNSFinal Results
17th Mar 20217:00 amRNSInvestor Webinar
16th Mar 20217:00 amRNSNet Asset Value(s)
25th Feb 20217:00 amRNSDividend Declaration
25th Feb 20217:00 amRNSTransaction in Own Shares & Total Voting Rights
23rd Feb 20219:52 amRNSIrrevocable Share Repurchase Programme
18th Feb 20217:00 amRNSTransaction in Own Shares & Total Voting Rights
16th Feb 20217:00 amRNSNet Asset Value(s)
29th Jan 20217:00 amRNSTransaction in Own Shares & Total Voting Rights
28th Jan 20217:00 amRNSTransaction in Own Shares & Total Voting Rights
25th Jan 20217:00 amRNSAdditional allocation under CBILS
22nd Jan 20217:00 amRNSTransaction in Own Shares
22nd Jan 20217:00 amRNSInvestment Manager's Holding
15th Jan 20217:00 amRNSNet Asset Value(s)
5th Jan 20217:00 amRNSTransaction in Own Shares & Total Voting Rights
31st Dec 20207:00 amRNSTransaction in Own Shares
22nd Dec 20205:08 pmRNSHolding(s) in Company
18th Dec 20205:43 pmRNSHolding(s) in Company
18th Dec 20207:00 amRNSTransaction in Own Shares & Total Voting Rights
17th Dec 20207:01 amRNSDividend reclassification
17th Dec 20207:00 amRNSNet Asset Value(s)
24th Nov 20207:00 amRNSTransaction in Own Shares & Total Voting Rights
16th Nov 20207:00 amRNSNet Asset Value(s)
9th Nov 20207:00 amRNSTransaction in Own Shares & Total Voting Rights
2nd Nov 20202:39 pmRNSDividend Declaration
29th Oct 20207:00 amRNSTransaction in Own Shares & Total Voting Rights
28th Oct 20207:00 amRNSTransaction in Own Shares
21st Oct 20207:00 amRNSInvestment Manager's Holding
16th Oct 20207:00 amRNSNet Asset Value(s)
16th Oct 20207:00 amRNSTransaction in Own Shares
12th Oct 202011:29 amRNSDirector Declaration
9th Oct 20204:27 pmRNSTransaction in Own Shares
8th Oct 20207:00 amRNSTransaction in Own Shares & Total Voting Rights
5th Oct 20207:00 amRNSTransaction in Own Shares & Total Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.